C12N2770/28034

Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
20210206812 · 2021-07-08 ·

The present invention relates to enveloped RNA viruses. The invention in particular relates to the generation of superior antigens for mounting an immune response by first identifying then mutating the immunosuppressive domains in fusion proteins of enveloped RNA viruses resulting in decreased immunosuppressive properties of viral envelope proteins from the viruses.

HEV vaccine

The present invention relates to a vaccine comprising Open Reading Frame 2 (ORF2) protein of Swine Hepatitis E virus (HEV) and a pharmaceutically acceptable carrier, for use in the protection of anti-HEV MDA-positive piglets against HEV fecal shedding.

Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
20240150409 · 2024-05-09 ·

The present invention relates to enveloped RNA viruses. The invention in particular relates to the generation of superior antigens for mounting an immune response by first identifying then mutating the immunosuppressive domains in fusion proteins of enveloped RNA viruses resulting in decreased immunosuppressive properties of viral envelope proteins from the viruses.

HEV VACCINE

The present invention relates to a vaccine comprising Open Reading Frame 2 (ORF2) protein of Swine Hepatitis E virus (HEV) and a pharmaceutically acceptable carrier, for use in the protection of anti-HEV MDA-positive piglets against HEV fecal shedding.